Aerie Pharma (AERI) Misses Q1 EPS by 8c

Aerie Pharma (NASDAQ: AERI) reported Q1 EPS of ($0.72), $0.08 worse than the analyst estimate of ($0.64).

As of March 31, 2016, Aerie had cash, cash equivalents, and investments of $130.8 million on the balance sheet. For the first quarter ended March 31, 2016, Aerie reported a net loss attributable to common stockholders, as measured in accordance with U.S. generally accepted accounting principles (“GAAP”), of $22.7 million, or $0.85 per share, compared to $17.2 million and $0.70 per share for the first quarter of 2015. The weighted average number of shares of common stock outstanding utilized in the calculation of net loss per common share was 26,723,266 and 24,602,668 for the first quarters of 2016 and 2015, respectively.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c